Icahn Blasts Forest Labs' Nondisclosure Of FDA Letter

Law360, New York (August 14, 2012, 3:38 PM EDT) -- Activist investor Carl Icahn on Monday turned up the heat in his proxy fight with Forest Laboratories Inc., ripping the drugmaker for not disclosing to investors a recent U.S. Food and Drug Administration warning letter over alleged off-label promotion of its chronic obstructive pulmonary disease drug Daliresp.

With Forest's annual shareholders' meeting set for Wednesday, Icahn, who is running another minority slate of company director nominees after a failed proxy fight last year, criticized Forest over the warning letter made public by the FDA last Tuesday...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.